MedTrace Logo

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT03647124 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2025-03-04

No results posted yet for this study

Summary

The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.

Conditions

  • Lymphoma, Mantle-Cell

Interventions

DRUG

Lenalidomide

Specified dose on specified days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2024-01-10
Completion
2024-01-10

Countries

  • Austria
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647124 on ClinicalTrials.gov